SciSparc Subsidiary NeuroThera Wins Japanese Patent for Novel Pain and Fever Therapy
TipRanks (Wed, 12-Aug 9:14 AM ET)
Globe Newswire (Wed, 12-Aug 8:25 AM ET)
SciSparc's NeuroThera Launches Phase IIb Trial at Yale for Pioneering Tourette Syndrome Treatment
Market Chameleon (Wed, 5-Aug 5:00 AM ET)
Globe Newswire (Wed, 5-Aug 8:22 AM ET)
SciSparc’s Quantum Platform Milestone Sets New Standard for Clinical Data Analytics
Market Chameleon (Fri, 31-Jul 5:18 AM ET)
Globe Newswire (Fri, 31-Jul 8:20 AM ET)
Market Chameleon (Wed, 29-Jul 7:07 AM ET)
Globe Newswire (Wed, 29-Jul 8:32 AM ET)
Globe Newswire (Mon, 27-Jul 8:25 AM ET)
Globe Newswire (Wed, 15-Jul 8:41 AM ET)
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Scisparc Ltd. - trades on the NASDAQ stock market under the symbol SPRC.
As of August 14, 2026, SPRC stock price declined to $6.59 with 7,818 million shares trading.
SPRC has a beta of 1.97, meaning it tends to be more sensitive to market movements. SPRC has a correlation of 0.02 to the broad based SPY ETF.
SPRC has a market cap of $3.73 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, SPRC traded as high as $2,687.56 and as low as $2.98.
SPRC has underperformed the market in the last year with a price return of -85.1% while the SPY ETF gained +21.5%. However, in the short term, SPRC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +32.3% vs +4.0% return in SPY. But in the last 2 weeks, SPRC shares have been beat by the market, returning -7.4% compared to an SPY return of +3.9%.
SPRC support price is $5.94 and resistance is $7.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRC shares will trade within this expected range on the day.